TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1532672
Drug: FUDR (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUDR (0.05 to 1.7 mg/kg/d) alone or combined with 5-FU and leucovorin
Study: 1532672
Drug: Combined intraarterial
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intraarterial treatment with LCV
Study: 1532672
Drug: Regional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional treatment
Study: 2992278
Drug: Estradiol transdermal
Normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol transdermal system, 0.1 mg/day
Study: 2992278
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens, 0.625 mg/day
Study: 2992278
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens, 1.25 mg/day
Study: 12535810
Drug: Spironolactone treatment
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone treatment
Study: 23830709
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) targeted to the C5‐C6 spinal segment
Study: 23830709
Drug: Sham spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham spinal manipulative therapy
Study: 12221393
Drug: 2% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% CHX solution + a 25% CHX‐containing controlled‐release device
Study: 12221393
Drug: Ca(OH)(2)+ 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)(2)+ 0.2% CHX gel
Study: 12221393
Drug: 0.2% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% CHX gel
Study: 7976413
Drug: Metyrapone (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (11 beta‐hydroxylase inhibitor) followed by growth hormone releasing hormone (1 microgram kg‐1 body wt)
Study: 7976413
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by growth hormone releasing hormone (1 microgram kg‐1 body wt)
Study: 29095263
Drug: Phenylephrine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (0.5 mL/kg/h, 5 mg/50 mL)
Study: 19735542
Drug: Integrative Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Medicine (IM) care with seven treatment sessions from two different types of complementary therapies over ten weeks.
Study: 19735542
Drug: Integrative Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Medicine (IM) care
Study: 19735542
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care (advice and prescription of analgesics)
Study: 9028311
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy followed by autologous hematopoietic progenitor cell transplantation with fractionated total body irradiation, etoposide (VP) 60 mg/kg, and cyclophosphamide (Cy) 100 mg/kg.
Study: 9028311
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy followed by autologous hematopoietic progenitor cell transplantation with BCNU 15 mg/kg, VP 60 mg/kg, and Cy 100 mg/kg.
Study: 9028311
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy followed by autologous hematopoietic progenitor cell transplantation with CCNU 15 mg/kg, VP 60 mg/kg, and Cy 100 mg/kg.
Study: 2438451
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight dextran solution
Study: 31298289
Drug: Ultrasound-guided perineural
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided perineural PRP injection and medical treatment
Study: 26654906
Drug: Microbial cell
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbial cell preparation (daily dosage of 6 × 10^10 CFU)
Study: 18227766
Drug: Nonpenetrating very
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpenetrating very deep sclerectomy (NPVDS) with reticulated hyaluronic acid implant (SKGEL)
Study: 11298610
Drug: 75 microg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 microg/kg/d intravenous (i.v.) anti-D
Study: 11298610
Drug: 50 microg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg/kg/d intravenous (i.v.) anti-D
Study: 9253562
Drug: Ondansetron 0.1
Normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.1 mg kg‐1
Study: 9253562
Drug: Droperidol 75
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droperidol 75 micrograms kg‐1 and Ondansetron 0.1 mg kg‐1
Study: 8310137
Drug: Conformal pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conformal pelvic radiotherapy (dose levels of 30‐38 Gy)
Study: 8310137
Drug: Conformal pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conformal pelvic radiotherapy (dose levels of 56‐65 Gy)
Study: 28097317
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plus 6 months of androgen deprivation therapy
Study: 26085515
Drug: HSF +
Normalized name: Hydroxyethyl Starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSF + DHA diet (3.45 g DHA/d and 0.5 g EPA/d)
Study: 23663917
Drug: Tailored regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored regimen (daily pills until three consecutive days bleeding triggers a 3‐day pill‐free interval) of Microgynon 30® (ethinyl oestradiol 30 mcg, levonorgestrel 150 mcg)
Study: 23663917
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (21 daily pills followed by a 7‐day pill‐free interval) of Microgynon 30® (ethinyl oestradiol 30 mcg, levonorgestrel 150 mcg)
Study: 20415935
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen arginate (PRE group)
Study: 20415935
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen arginate (POST group)
Study: 19433378
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of the campaign and a cognitive-behavioral small group intervention
Study: 14983952
Drug: Screening with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening with transrectal ultrasonography (TRUS) and sextant prostate biopsy when PSA >4 ng/mL (or >2.9 ng/mL after May 1998)
Study: 10919682
Drug: Salbutamol 200
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 200 microg four times daily via HFA 134a pMDI (Ventolin CFC-free)
Study: 10919682
Drug: Salbutamol 200
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 200 microg four times daily via CFC pMDI (Ventolin)
Study: 8639796
Drug: Working Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Working Formulation (WF) - intermediate/high-grade
Study: 8639796
Drug: Working Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Working Formulation (WF) - low-grade
Study: 29345992
Drug: Substance use
Normalized name: reSET Substance Use Disorder Therapy Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance use disorder treatment in jail
Study: 27650051
Drug: Intramuscular betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular betamethasone (11.4 mg Celestone Chronodose), repeated weekly if risk of very preterm birth remained
Study: 27650051
Drug: Saline placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo, repeated weekly if risk of very preterm birth remained
Study: 27650051
Drug: Intramuscular betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular betamethasone (11.4 mg Celestone Chronodose)
Study: 25024623
Drug: BM‐MNCs transplantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM‐MNCs transplantation plus routine medical treatment
Study: 17446823
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment only (Control)
Study: 16094217
Drug: MMRV (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV (1 dose)
Study: 16094217
Drug: MMRV (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV (2 doses)
Study: 16094217
Drug: M‐M‐RII and
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐M‐RII and VARIVAX (1 dose)
Study: 12477671
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg dolasetron i.v.
Study: 12477671
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg metoclopramide i.v.
Study: 10652047
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate (0.5 mg/kg) administered at the time of transplantation and again one month later
Study: 9037847
Drug: Nisoldipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10 mg daily)
Study: 1370735
Drug: Continuous aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous aprotinin infusion (0.1‐0.4 Mill. KIU/hr)
Study: 1370735
Drug: Continuous aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous aprotinin infusion
Study: 6380717
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of radiotherapy and local external hyperthermia
Study: 6380717
Drug: Immediate combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate combination of heat and large radiation fractions
Study: 6380717
Drug: Highest hyperthermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest hyperthermic treatment and largest radiation fractions
Study: 29241357
Drug: CBD (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (1000 mg/day)
Study: 9028551
Drug: Intravenous CMV
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CMV hyperimmune globulin (0.4 g/kg on day -8, 0.2 g/kg on days -1, +7, +14, +21, +28, +35, +42, +56, +70)
Study: 11136142
Drug: Lidocaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2 mg/kg)
Study: 31755634
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and treatment for HCV
Study: 31301054
Drug: CoQun® (ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQun® (ophthalmic solution of Coenzyme Q10 and Vitamin E)
Study: 28489775
Drug: Nimodipine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 7.5 μg/(kg × h) injected 30 minutes before anesthesia induction
Study: 21565138
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Kangliu Zengxiao Decoction (KLZX)
Study: 21565138
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with KLZX
Study: 11014951
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (200 mg/day)
Study: 11014951
Drug: Intravenous albumin
Normalized name: albumin human, USP Injection [Albuminar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous albumin (100 ml of 20%)
Study: 9241103
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1 g day(‐1) for 4 weeks
Study: 24956496
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (telaprevir, ribavirin, pegylated-interferon alfa)
Study: 24956496
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (boceprevir, ribavirin, pegylated-interferon alfa)
Study: 22079391
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (Q10) supplementation at a dose of 90 mg daily for 8 weeks
Study: 18386567
Drug: Rhubarb combined
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb combined with enteral nutrition (10% rhubarb liquid medication, 100 mL before operation, 50 mL at 18th and 42th hour post-operation)
Study: 18386567
Drug: Conventional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fluid supplement and parenteral nutrition
Study: 12537464
Drug: Moderate beer
Normalized name: BEER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate beer consumption (330 mL of beer/day for 30 days)
Study: 8340155
Drug: Ridogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridogrel (300 mg)
Study: 3032537
Drug: Guar administration
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar administration (5-g minitablets, three times per day with main meals for 8 weeks)
Study: 3032537
Drug: Guar administration
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar administration
Study: 31522924
Drug: Smartphone application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone application (app) for reporting symptoms, used weekly or sooner if symptoms worsened
Study: 31337168
Drug: Interfascial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interfascial injection (IF Group)
Study: 31337168
Drug: Perivascular injection
Normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perivascular injection with nerve stimulation (PV Group)
Study: 27337795
Drug: 10 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 Hz rTMS delivered to the left dorsolateral prefrontal cortex, 2 times daily for 10 days
Study: 23819344
Drug: Fixed-dose perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose perindopril and amlodipine combination
Study: 16614584
Drug: Fast-track treatment
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-track treatment
Study: 10765092
Drug: Orchiectomy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchiectomy combined with adjuvant mitomycin C (MMC; 15 mg/m(2) i.v. q 6 weeks)
Study: 8889684
Drug: Ethanol (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0, 0.28, 0.52 g/kg)
Study: 8889684
Drug: Cocaine (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (4, 48, 96 mg/70 kg)
Study: 8889684
Drug: Drug Recognition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Recognition Examiner (DRE) assessments
Study: 31050707
Drug: pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab (200 mg every 3 weeks)
Study: 31050707
Drug: chemotherapy (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy (paclitaxel 175 mg/m2, docetaxel 75 mg/m2, or vinflunine 320 mg/m2, all every 3 weeks)
Study: 29139592
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g single dose systemic acetaminophen
Study: 29139592
Drug: Oral opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral opioid consumption
Study: 25596179
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF, 300 mg/day) monotherapy
Study: 25596179
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF, 300 mg/day) and entecavir (ETV, 1 mg/day) combination therapy
Study: 22039171
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) delivered orally (50 mg)
Study: 22039171
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) delivered to proximal small bowel (PSB) (50 mg)
Study: 22039171
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) delivered to distal small bowel (DSB) (50 mg)
Study: 22039171
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) delivered to ascending colon (AC) (50 mg)
Study: 15043687
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg melatonin for 1 week
Study: 9497182
Drug: 10% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbohydrate solution (CHO; 170 +/- 6 g glucose)
Study: 9497182
Drug: 10% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbohydrate electrolyte with 5% MCT solution (CHO + MCT; 85 +/- 3 g MCT)
Study: 9497182
Drug: 5% MCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% MCT solution
Study: 8803911
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy including hydroxychloroquine, methotrexate, and sulphasalazine
Study: 6988172
Drug: Feprazone (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feprazone (800 mg daily for 2 days, then 600 mg daily for up to 8 days)
Study: 6988172
Drug: Phenylbutazone (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (800 mg daily for 2 days, then 600 mg daily for up to 8 days)
Study: 25780062
Drug: Exercise plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise plus chemotherapy (cyclophosphamide)
Study: 16750207
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (40 mg every second day)
Study: 16750207
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate (2 mg daily)
Study: 17341565
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of testosterone and estradiol
Study: 15761754
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration of enalaprilat (>50 ng/ml)
Study: 15761754
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration of enalaprilat (<10 ng/ml)
Study: 12082361
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 5 mg/day
Study: 12082361
Drug: Micronized, oil-suspended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized, oil-suspended progesterone 200 mg/day
Study: 8701750
Drug: Huperzine-A (Hup)
Normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine-A (Hup) 0.2 mg (4 tablets) orally, twice daily for 8 weeks
Study: 8701750
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 tablets) orally, twice daily for 8 weeks
Study: 2140961
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (ANF) infusion (1.95 pmol/min per kg)
Study: 2140961
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg, administered orally) with physiological saline (placebo)
Study: 31289040
Drug: Nivolumab and
Normalized name: nivolumab and relatlimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab and ipilimumab (peri-operative immunotherapy)
Study: 27988849
Drug: Negative-pressure wound
Normalized name: Microcyn Negative-Pressure Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure wound therapy (NPWT) and antibiotic treatment after surgical debridement
Study: 9494145
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (60 mg daily)
Study: 21646599
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg once daily (N=65)
Study: 21646599
Drug: Metoprolol 95
Normalized name: metoprolol 95 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 95 mg once daily (N=63)
Study: 16410677
Drug: Cabergoline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (1 mg/day) + Clarithromycin (400 mg/day) for 6 days
Study: 16410677
Drug: Cabergoline (stable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (stable doses) + Clarithromycin (400 mg/day) for 6 days
Study: 16410677
Drug: Cabergoline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (1 mg/day) for 6 days
Study: 11306204
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogens 0.625 mg/day for 28 days plus MAP 10 mg/day for the last 14 days
Study: 11306204
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 mcg every 7 days for 28 days plus MAP 10 mg/day from 15th to 28th day
Study: 1907317
Drug: DTP vaccine
Normalized name: DTP Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP vaccine
Study: 9272339
Drug: DT vaccine
Normalized name: Diphtheria Toxoid, Adsorbed/Tetanus Toxoid Intramuscular Suspension [DT VACCINE ADSORBED PEDIATRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DT vaccine